Depending on cancer characteristics, first-line therapy for advanced CRC is combination chemotherapy plus an anti-epidermal growth factor receptor (EGFR) antibody or anti-vascular endothelial growth factor (VEGF) [4, 5]; however, progression-free survival time for most patients is within 9–12 months [6–13]. This evidence concerns the gene EGFR and colorectal carcinoma.